Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunrise Looking To International Markets For Hyperion LTK Hyperopia System

This article was originally published in The Gray Sheet

Executive Summary

Sunrise Technologies is looking toward international market opportunities for its Hyperion laser thermal keratoplasty (LTK) ophthalmic Holmium laser system following a July 22 "not approvable" recommendation for treatment of hyperopia from FDA's Ophthalmic Devices Panel (1"The Gray Sheet" July 26, p. 3).

You may also be interested in...



Deficient Long-Term Data Render Sunrise Hyperopia Tool Not Approvable

Forty-six percent of the eyes treated with Sunrise Technologies' Hyperion laser thermal keratomileusis (LTK) system for hyperopia in clinical trials were under-corrected by greater than 1.00 diopter twenty-four months post-treatment, data contained in the firm's premarket approval application showed.

REFRACTIVE SURGERY LASER REVISED DRAFT IDE GUIDANCE INCLUDES HIGH MYOPIA AND HYPEROPIA, WITH OR WITHOUT ASTIGMATISM; POLICY SLATED FOR PANEL REVIEW OCT. 21

Refractive lasers used to treat high myopia should provide uncorrected visual acuity (UCVA) of 20/40 or better in at least 75% of postoperative eyes, FDA says in a draft revision of its "Checklist of Information Usually Submitted in an Investigational Device Exemption for Refractive Surgery Lasers." The draft, released Sept. 5, defines high myopia as greater than -7.00 diopters, with or without astigmatism. For hyperopia (with or without astigmatism), the target endpoint for UCVA of 20/40 cited is 85%.

UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel